1-2 of 2
Yun Shaw
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

Clinical Trials & Observations
John C. Byrd, Richard R. Furman, Steven E. Coutre, Jan A. Burger, Kristie A. Blum, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Yun Shaw, Elizabeth Bilotti, Cathy Zhou, Danelle F. James, Susan O'Brien
Journal: Blood
Blood (2015) 125 (16): 2497–2506.
https://doi.org/10.1182/blood-2014-10-606038
Published: 2015
Includes: Supplemental data
Journal Articles

The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-Term Safety and Durability Of Response In Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients In An Open-Label Extension Study

Susan O'Brien, MD, Richard R. Furman, MD, Nathan Fowler, MD, Steven E. Coutre, MD, Jeff P. Sharman, MD, Kristie A. Blum, MD, Jan A. Burger, MD, PhD, Jeffrey A. Jones, MD, MPH, William G. Wierda, MD, PhD, Emiliano Mugnaini, MD, Ian Flinn, MD, PhD, Ranjana H. Advani, MD, Kathryn S. Kolibaba, MD, Yun Shaw, Fong Clow, ScD, Danelle F. James, MD, Alvina D. Chu, MD, John C. Byrd, MD
Journal: Blood
Blood (2013) 122 (21): 4163.
https://doi.org/10.1182/blood.V122.21.4163.4163
Published: 2013